Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.51 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70027 | 0.84 | NPSR1 (0.67) | NPSR1LMNAPPARGNCOA1NCOA3 | |
| SCHEMBL7219808 | 0.82 | HDAC3 (0.59) | GSK3BLMNAHPGDL3MBTL1TSHR | |
| SCHEMBL15079224 | 0.81 | GSK3B (0.51) | GSK3BNPSR1LMNAPPARGNCOA1 | |
| SCHEMBL18153171 | 0.80 | GSK3B (0.64) | GSK3BPOLBRAB9A | |
| SCHEMBL6360802 | 0.79 | NPSR1 (0.49) | GSK3BNPSR1LMNAPPARGNCOA1 | |
| SCHEMBL16753170 | 0.78 | GSK3B (0.49) | GSK3BNPSR1PPARGNCOA2HPGD | |
| SCHEMBL1303016 | 0.78 | NPSR1 (0.60) | NPSR1LMNAPPARGNCOA1NCOA3 | |
| SCHEMBL348559 | 0.78 | LMNA (0.51) | NPSR1LMNAPPARGNCOA1NCOA3 | |
| SCHEMBL27529610 | 0.77 | NPSR1 (0.54) | GSK3BNPSR1LMNAPPARGNCOA1 | |
| SCHEMBL277203 | 0.76 | LMNA (0.58) | GSK3BNPSR1LMNAPPARGNCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558494-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | ITALFARMACO S.p.A. (IT) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017897-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | ITALFARMACO S.P.A. (IT) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024017897-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | ITALFARMACO S.P.A. (IT) | 2024-01-25 | — | — | WO | disclosed |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2023-07-04 | — | — | US | disclosed |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2023-07-04 | — | — | US | disclosed |
| CN-110372692-B | Dihydroquinazolinone reverse transport process blocker, and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2020-10-23 | — | — | CN | disclosed |
| EP-3283464-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3283464-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10081617-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180105507-A1 | ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2018-04-19 | — | — | US | disclosed |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005079791-A1 | THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1289980-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001090100-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-29 | — | — | WO | disclosed |
| EP-0021840-B1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1983-08-31 | — | — | EP | disclosed |
| US-4316907-A | Heterocyclic compounds, processes for their preparation and their use | GLAXO GROUP LIMITED (GB) | 1982-02-23 | — | — | US | disclosed |
| EP-0021840-A1 | Heterocyclic compounds, processes for their preparation and compositions containing them | GLAXO GROUP LIMITED (GB) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105507-A1 | ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS | FOXO1, FOXO3, BCOR | GSK3B 4163/4885NPSR1 4656/4885LMNA 4433/4885 |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | GSK3B 4101/4885NPSR1 829/4885LMNA 2988/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | GSK3B 4108/4885NPSR1 1061/4885LMNA 3270/4885 |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | CASP1, IL1B, OXER1 | GSK3B 2867/4885NPSR1 2413/4885LMNA 2661/4885 |
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | GSK3B 198/4885NPSR1 3361/4885LMNA 3906/4885 |
| US-10081617-B2 | Factor XIa inhibitors | F11, F2, TFPI | GSK3B 366/4885NPSR1 3450/4885LMNA 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.